Related Experiment Video
Updated: Jan 20, 2026

Endotoxin Activity Assay for the Detection of Whole Blood Endotoxemia in Critically Ill Patients
Published on: June 24, 2019
Robustness of sepsis-3 criteria in critically ill patients
Diana M Verboom1,2, Jos F Frencken1,2, David S Y Ong1,3
11Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Background:
Early recognition of sepsis is challenging, and diagnostic criteria have changed repeatedly. We assessed the robustness of sepsis-3 criteria in intensive care unit (ICU) patients.
Methods:
We studied the apparent incidence and associated mortality of sepsis-3 among patients who were prospectively enrolled in the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) cohort in the Netherlands, and explored the effects of minor variations in the precise definition and timing of diagnostic criteria for organ failure.
Results:
Among 1081 patients with suspected infection upon ICU admission, 648 (60%) were considered to have sepsis according to prospective adjudication in the MARS study, whereas 976 (90%) met sepsis-3 criteria, yielding only 64% agreement at the individual patient level. Among 501 subjects developing ICU-acquired infection, these rates were 270 (54%) and 260 (52%), respectively (yielding 58% agreement). Hospital mortality was 234 (36%) vs 277 (28%) for those meeting MARS-sepsis or sepsis-3 criteria upon presentation (p < 0.001), and 121 (45%) vs 103 (40%) for those having sepsis onset in the ICU (p < 0.001). Minor variations in timing and interpretation of organ failure criteria had a considerable effect on the apparent prevalence of sepsis-3, which ranged from 68 to 96% among those with infection at admission, and from 22 to 99% among ICU-acquired cases.
Conclusion:
The sepsis-3 definition lacks robustness as well as discriminatory ability, since nearly all patients presenting to ICU with suspected infection fulfill its criteria. These should therefore be specified in greater detail, and applied more consistently, during future sepsis studies.
Trial Registration:
The MARS study is registered at ClinicalTrials.gov (identifier NCT01905033).
Related Concept Videos
06:28Endotoxin Activity Assay for the Detection of Whole Blood Endotoxemia in Critically Ill Patients
09:44Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients
07:42A Data-Driven Approach to Quantifying Immune States in Sepsis
11:02Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
07:16An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
14:54A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

